RxDoctor Payments Data

David Morrison

Long Beach, CANPI 1326027947

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $4,203,937 of the $4,204,397 with a category attached, or 100.0%. Arthrex accounts for 100.0% of it on its own, with 8 other manufacturers making up the rest.

$4,204,397in general payments, 2019–2025

Across 50 payments — averaging $84,088 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$4.2M
  • Pfizer$258
  • Incyte Corporation$44
  • Sun Pharmaceutical Industries Inc.$38
  • Takeda Pharmaceuticals U.S.A., Inc.$31
  • Dendreon Pharmaceuticals LLC$30
  • plus $58 from 3 others

What the payments were for

  • Royalty or licence$4,203,937100%
  • Food & beverage$4590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →